<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20241214064051N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-02-15</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparative Study of Corticosteroid Injection in the Caudal Epidural Space Under Fluoroscopy Guidance With or Without Ozone Injection in Lumbo-Sacral Radiculopathy: A Single-Blind Clinical Trial</public_title>
      <acronym></acronym>
      <scientific_title>Comparative Study of Corticosteroid Injection in the Caudal Epidural Space Under Fluoroscopy Guidance With or Without Ozone Injection in Lumbo-Sacral Radiculopathy: A Single-Blind Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-01-24</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/81330</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research, Randomization description: Forty patients meeting the inclusion criteria will be randomly assigned into two groups of 20 patients each using a computer-generated randomization list. Group A will receive a caudal epidural steroid injection, while Group B will receive the same injection plus ozone therapy. The participants and the physician assessing outcomes will be blinded to the type of procedure, though the operator performing the injections will be aware of the treatment administered, Blinding description: In our randomized controlled trial comparing fluoroscopic-guided caudal epidural steroid injections with or without ozone therapy, we implemented blinding in specific groups to minimize bias. Below is a detailed description of the blinding process and its application to various roles involved in the study.

1. Participants (Patients) – Blinded ✅
The patients were unaware of which treatment they received (steroid injection alone or steroid + ozone injection). Since the injections were performed under the same procedural conditions for both groups, no distinguishing factors indicated the treatment assignment.

2. Principal Investigator – Not Blinded ❌
The principal investigator was involved in study design and oversight but was not blinded to treatment allocation. Given the need for procedural oversight and protocol adherence, they had access to treatment assignment information.

3. Healthcare Providers (Care Providers/Interventionists) – Not Blinded ❌
The physician performing the injections was aware of the treatment allocation since they had to prepare and administer the correct mixture. Due to the nature of the intervention (i.e., the inclusion of ozone gas in one group), it was not possible to blind the care provider.

4. Data Collectors – Blinded ✅
All data collectors, including those responsible for recording patient-reported pain scores and functional disability assessments, were blinded to the treatment assignment. This ensured that subjective measures such as the Visual Analog Scale (VAS) and the Oswestry Disability Index (ODI) were not influenced by knowledge of group allocation.

5. Outcome Assessors – Blinded ✅
The physician assessing clinical outcomes (pain and disability scores) was blinded to the treatment groups. Outcome assessments were conducted at baseline, 1 month, and 6 months post-procedure without knowledge of whether the patient received steroids alone or steroids plus ozone.

6. Data Analysts – Blinded (Unclear, Needs Clarification) ❓
The data analyst responsible for statistical analyses may or may not have been blinded. If blinding was applied, the dataset would have been coded in a way that concealed treatment allocation. If unblinded, this may have introduced potential bias in the interpretation of results.

7. Data Safety and Monitoring Board (DSMB) – Not Applicable ❌
The study did not include an independent Data Safety and Monitoring Board (DSMB), as it was a relatively small-scale clinical trial without external oversight.

8. Manuscript Writers – Not Blinded ❌
The authors of the manuscript had access to full study data and treatment allocation, which allowed for an informed discussion of results and clinical implications.

Summary of Blinding Implementation
Group	Blinding Status	Rationale
Participants (Patients)	✅ Blinded	Ensured unbiased patient-reported outcomes (VAS, ODI).
Principal Investigator	❌ Not Blinded	Required for study design and oversight.
Care Providers (Interventionists)	❌ Not Blinded	Needed to prepare and administer treatment.
Data Collectors	✅ Blinded	Ensured unbiased data collection of patient responses.
Outcome Assessors	✅ Blinded	Prevented bias in evaluating clinical outcomes.
Data Analysts	❓ Unclear	Should ideally be blinded to prevent bias in analysis.
DSMB	❌ Not Applicable	No external monitoring board was used.
Manuscript Writers	❌ Not Blinded	Required access to complete data for reporting.
How Blinding Was Achieved
Randomization: Patients were randomly assigned to two treatment groups using a computer-generated randomization list.
Standardized Procedures: Both groups underwent identical procedural steps, making it difficult for patients to distinguish between treatments.
Separate Roles: The care provider (interventionist) was separate from the outcome assessor, ensuring the assessment process remained unbiased.
Blinded Data Collection: The individuals collecting VAS and ODI scores were unaware of treatment allocation.
Potential Data Analysis Blinding: If implemented, treatment codes were masked until the final statistical analysis was completed.</study_design>
      <phase>3</phase>
      <hc_freetext>Lumbosacral Radiculopathy due to Lumbar Intervertebral Disc Protrusion (L4-L5 or L5-S1).This study focuses on chronic low back pain (LBP) with radicular symptoms, aiming to improve pain management and functional outcomes for patients with this condition..</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group:Group B (Steroid + Ozone Group):This group will receive the same steroid injection as the control group, with the addition of ozone gas.Injection Details:Steroid Composition:8 mg dexamethasone.5 mL of 1% lidocaine.3 mL of normal saline.Additional Component:5 mL of ozone gas at a concentration of 10 µg/cc.Procedure:All injections will be performed under fluoroscopic guidance in a sterile environment to ensure precise catheter placement in the epidural space. Intervention 2: Control group:Group A (Steroid Group):This group will serve as the control group in the study and will receive only the steroid injection.Injection Details:Steroid Composition:8 mg dexamethasone.5 mL of 1% lidocaine.3 mL of normal saline.Procedure:All injections will be performed under fluoroscopic guidance in a sterile environment to ensure precise catheter placement in the epidural space.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is It is not yet known if there will be a plan to make this available</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nima Amiresmaili</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini Hospital, Keshavarz Boulevard, Tehran, Iran. Postal Code: 1419733141</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733141</zip>
        <telephone>+98 911 218 2557</telephone>
        <email>nima.amiresmaili@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nima Amiresmaili</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehran, Enghelab Square, 16 Azar Street, Central Building of the University of Tehran.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733141</zip>
        <telephone>+98 21 6646 9824</telephone>
        <email>nima.amiresmaili@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 18 and 70 years
Diagnosed with low back pain (LBP) with radicular symptoms  lasting more than three months and unresponsive to medical therapy, rest, and physical therapy
Magnetic resonance imaging (MRI) evidence of lumbar intervertebral disc protrusion at the L4-L5 or L5-S1 levels</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of spinal fractures, inflammatory diseases, malignancy, or facet joint syndrome.
Previous spinal surgeries
uncontrolled diabetes mellitus
neuropathy
spondylolisthesis
extruded discs
severe knee osteoarthritis (grade 4),
scoliosis
clinical or laboratory evidence of infection
Coagulopathy
symptoms of cauda equina syndrome
symptoms of cauda equina syndrome
neurological disorders
severe systemic diseases, mental illnesses
current anticoagulant therapy
Pregnancy or breastfeeding</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M51.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Thoracic, thoracolumbar and lumbosacral intervertebral disc disorders with radiculopathy</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group:Group B (Steroid + Ozone Group):This group will receive the same steroid injection as the control group, with the addition of ozone gas.Injection Details:Steroid Composition:8 mg dexamethasone.5 mL of 1% lidocaine.3 mL of normal saline.Additional Component:5 mL of ozone gas at a concentration of 10 µg/cc.Procedure:All injections will be performed under fluoroscopic guidance in a sterile environment to ensure precise catheter placement in the epidural space.</i_keyword>
      <i_keyword>Control group:Group A (Steroid Group):This group will serve as the control group in the study and will receive only the steroid injection.Injection Details:Steroid Composition:8 mg dexamethasone.5 mL of 1% lidocaine.3 mL of normal saline.Procedure:All injections will be performed under fluoroscopic guidance in a sterile environment to ensure precise catheter placement in the epidural space.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain IntensityMeasurement Method: Visual Analog Scale (VAS)Scale Range: 0 (No Pain) to 10 (Worst Pain Imaginable)Objective: To assess the patient's pain intensity before and after the intervention to determine treatment efficacy.Measurement Time Points: Baseline, 1 month, and 6 months post-injection. Timepoint: Pain IntensityMeasurement Method: Visual Analog Scale (VAS)Scale Range: 0 (No Pain) to 10 (Worst Pain Imaginable)Objective: To assess the patient's pain intensity before and after the intervention to determine treatment efficacy.Measurement Time Points:Before intervention (Baseline)1 month post-injection3 months post-injection6 months post-injection✅ The measurement time points are clearly specified.✅ The measurement method and scale range are explicitly stated. Method of measurement: Pain IntensityMeasurement Method: Visual Analogue Scale for PainMeasurement Tool: Visual Analogue Scale Ruler for PainScale Range: 0 (No Pain) to 10 (Worst Pain Imaginable)Objective: To assess the patient's pain intensity before and after the intervention to determine treatment efficacy.Measurement Time Points:Before the intervention (Baseline)One month after injectionThree months after injectionSix months after injection.</prim_outcome>
      <prim_outcome>Functional Disability. Timepoint: Before the intervention (Baseline)One month after injectionThree months after injectionSix months after injection. Method of measurement: Measurement Method: Oswestry Disability IndexMeasurement Tool: Oswestry Disability Index QuestionnaireUnit of Measurement: Percentage of functional disability caused by low back painObjective: To assess the effect of treatment on patients' functional ability and reduction of limitations caused by pain Measurement.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Quality of Life. Timepoint: Time Points:Before the intervention (Baseline)One month after injectionThree months after injectionb Six months after injection. Method of measurement: Measurement Method: World Health Organization Quality of Life Questionnaire Measurement Tool: World Health Organization Quality of Life Questionnaire – Short Version (26 Questions)Unit of Measurement: Quality of life score based on participants' responses.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-10-28</approval_date>
        <contact_name>The Ethics Committee of Human Research at Imam Khomeini Hospital.</contact_name>
        <contact_address>Imam Khomeini Hospital, Keshavarz Boulevard, Tehran, Iran tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
